<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Common Serodiagnostic Tests - Medical Microbiology</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- KaTeX for Math rendering -->
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/katex.min.css">
    <script defer src="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/katex.min.js"></script>
    <script defer src="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/contrib/auto-render.min.js" onload="renderMathInElement(document.body, {
        delimiters: [
            {left: '$$', right: '$$', display: true},
            {left: '$', right: '$', display: false}
        ]
    });"></script>
    
    <link rel="stylesheet" href="../styles/main.css">
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                
                <!-- TOP NAVIGATION -->
                <nav class="document-nav" role="navigation" aria-label="Document Navigation">
                    <div class="nav-links">
                        <a href="topic-04-in-vitro-reactions.html" class="nav-button nav-button--previous">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <a href="../index.html" class="nav-button">
                            <span class="nav-icon">üè†</span>
                            <span class="nav-text">Home</span>
                        </a>
                        
                        <a href="#" class="nav-button nav-button--next disabled" aria-disabled="true">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div>
                        </div>
                        <span class="progress-text">Topic 5 of 5</span>
                    </div>
                </nav>

                <header class="document-header">
                    <div class="header-badge">
                        <span>üß™</span>
                        <span>Topic 05</span>
                    </div>
                    <h1 class="document-title">Common Serodiagnostic Tests</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Basic Immunology and Serodiagnosis</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>20 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <p>Techniques of some serological tests which are commonly performed in a clinical laboratory are described here.</p>

                    <!-- Section 1: Febrile Agglutinins -->
                    <section class="content-section" id="febrile-agglutinins">
                        <div class="section-header">
                            <div class="section-number">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">üå°Ô∏è</span>
                                Detection of Febrile Agglutinins
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Febrile agglutinins are antibodies present in the sera of patients with some infectious diseases characterized by the presence of persistent fever of unknown aetiology. Such a condition is referred to as pyrexia of unknown origin (PUO). The antibodies are demonstrable <em>in vitro</em> by their ability to agglutinate corresponding bacterial antigens.</p>
                            <p>Febrile agglutination tests have been used in the diagnosis of infections with organisms such as</p>
                            <p>A. Salmonella species (Widal Test)<br>
                            B. Brucella species (SAT‚Äîstandard agglutination test)<br>
                            C. Rickettsiae (Weil‚ÄîFelix Test)</p>

                            <h3>A. Widal Test</h3>
                            <p>Widal test is a tube agglutination test for the detection of antibodies for the diagnosis of enteric fevers (typhoid and paratyphoid) caused by <em>Salmonella</em> species, namely, <em>Salmonella typhi</em>, <em>S. paratyphi A</em>, <em>S. paratyphi B</em> and <em>S. paratyphi C</em>. The 'O' (somatic or cell wall) antigens and 'H' (flagellar) antigens of each species are required for the test.</p>
                            <p><strong>Specimen:</strong> Patient's serum</p>
                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ÑπÔ∏è</span>
                                    <h4 class="callout-title">Note</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Antibodies to <em>Salmonella</em> antigens do not appear in the patient's serum until about the eighth day of fever. Therefore, a blood sample collected in less than one week after the onset of fever may give a false negative result.</p>
                                </div>
                            </div>

                            <h4>Reagents</h4>
                            <p>(i) Antigen Suspensions</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(a) O antigens: <em>Salmonella typhi</em> (TO), <em>S. paratyphi A</em> (AO), <em>S. paratyphi B</em> (BO) and <em>S. paratyphi C</em> (CO) antigen suspensions. O or somatic antigens are obtained by treatment of appropriate bacterial suspension with alcohol to destroy the H antigens. The suspension can also be heated at $100^{\circ}\mathrm{C}$ for 20-30 minutes to destroy the flagella, centrifuged and then resuspended in saline.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">(b) 'H' antigens <em>Salmonella typhi</em> (TH), <em>S. paratyphi A</em> (AH), <em>S. paratyphi B</em> (BH) and <em>S. paratyphi C</em> (CH). 'H' or flagellar antigens are obtained by treatment of the respective bacterial suspension with formaldehyde to destroy O antigens and fix the flagella.</span>
                                </li>
                            </ul>
                            <p><strong>Note:</strong> Stained antigen suspensions in a concentrated form with a colour code (blue for O, pink for H) are commercially available.</p>
                            <p>(ii) Physiological (0.85%) saline<br>
                            (iii) Positive control serum: Polyvalent O and H antisera for Salmonella species.</p>

                            <h4>Technique</h4>
                            <p><strong>Screening Test</strong></p>
                            <p>Before performing the tube agglutination test, a screening test should be performed on the serum against each antigen listed above.</p>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Using an agglutination tile, place one drop (0.02 ml) of patient's serum into eight wells, one well for each antigen. Add one drop of appropriate antigen to each well. Two wells, for a positive control and a saline control, should be included for each antigen suspension.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Using separate wooden applicator sticks, mix the contents of each well, spreading over the entire well surface.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Rotate the tile at approximately 180/rpm for three minutes on a rotator or rotate manually.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Observe for agglutination, preferably in a transmitted light. The positive controls must show obvious agglutination, negative controls show uniform suspensions.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Any agglutination observed with patient's serum must be tested further by tube agglutination test.</span></li>
                            </ul>

                            <p><strong>Tube agglutination test</strong></p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Set up ten (13 √ó 100 mm) test tubes for each antigen to be tested, namely TO, TH, AO, AH, BO, BH, CO and CH, or the antigens which are agglutinated by the patient's serum in the screening procedure.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Prepare doubling dilutions of patient's serum in saline, starting with 1:10 dilution for the H antigens as shown in the protocol as follows:</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Pipette 0.1 ml of patient's serum in tube 1 (1:10 dilution), mix and transfer 0.5 ml to tube 2 (1:20 dilution). Continue serial two-fold dilution till tube 8, the dilutions range from 1:10 to 1:1280. Discard 0.5 ml from tube 8.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">To tube 9, add one drop of the appropriate control serum.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Tube 10 serves as a saline control.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dilute the appropriate antigen 1:100 (or according to manufacturer's instructions) with saline (e.g. 0.1 ml of antigen + 9.9 ml of saline).</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Add 0.5 ml of dilute antigen to each tube (from 1 to 10) so that the final dilution ranges from 1:20 to 1:2560.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Repeat the same steps for each antigen to be tested.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Mix well. Incubate the tubes at 37¬∞C waterbath for 18 to 24 hours.</span></li>
                            </ol>

                            <p><strong>Note:</strong> If concentrated antigen suspension is used:</p>
                            <p>(i) Add one drop of the suspension to each tube of dilution.<br>
                            (ii) Start serum dilutions from 1:20 to 1:2560.<br>
                            (iii) The final dilution of the serum remains the same i.e. 1:20 to 1:2560.</p>

                            <h4>Reading Results</h4>
                            <p>Observe the tubes for agglutination in good light. Read as</p>
                            <p>++++ Complete agglutination, clear supernatant<br>
                            +++ Nearly complete agglutination, supernatant 75% clear<br>
                            ++ Significant agglutination, supernatant 50% clear<br>
                            + Observable agglutination, supernatant as dense as the negative control<br>
                            - No agglutination, supernatant as dense as the negative control</p>

                            <div class="table-wrapper">
                                <div class="table-header">
                                    <span class="table-icon">üìä</span>
                                    <span class="table-title">Protocol for Widal tube agglutination test</span>
                                </div>
                                <div class="table-container">
                                    <table class="content-table">
                                        <thead>
                                            <tr>
                                                <th>Tube No.</th>
                                                <th>1</th>
                                                <th>2</th>
                                                <th>3</th>
                                                <th>4</th>
                                                <th>5</th>
                                                <th>6</th>
                                                <th>7</th>
                                                <th>8</th>
                                                <th>9</th>
                                                <th>10</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>Saline (ml)</td>
                                                <td>0.9</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td></td>
                                                <td></td>
                                            </tr>
                                            <tr>
                                                <td>Patient's Serum (ml)</td>
                                                <td>0.1</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5 (discard)</td>
                                                <td></td>
                                                <td></td>
                                            </tr>
                                            <tr>
                                                <td>Dilution</td>
                                                <td>1:10</td>
                                                <td>1:20</td>
                                                <td>1:40</td>
                                                <td>1:80</td>
                                                <td>1:160</td>
                                                <td>1:320</td>
                                                <td>1:640</td>
                                                <td>1:1280</td>
                                                <td>‚Äî</td>
                                                <td>‚Äî</td>
                                            </tr>
                                            <tr>
                                                <td>Positive Control Serum</td>
                                                <td>‚Äî</td>
                                                <td>‚Äî</td>
                                                <td>‚Äî</td>
                                                <td>‚Äî</td>
                                                <td>‚Äî</td>
                                                <td>‚Äî</td>
                                                <td>‚Äî</td>
                                                <td></td>
                                                <td>1 Drop</td>
                                                <td>‚Äî</td>
                                            </tr>
                                            <tr>
                                                <td>Dilute Antigen (ml)</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                                <td>0.5</td>
                                            </tr>
                                            <tr>
                                                <td>Final Dilution of Serum</td>
                                                <td>1:20</td>
                                                <td>1:40</td>
                                                <td>1:80</td>
                                                <td>1:160</td>
                                                <td>1:320</td>
                                                <td>1:640</td>
                                                <td>1:1280</td>
                                                <td>1:2560</td>
                                                <td></td>
                                                <td></td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </div>
                            </div>

                            <h4>Interpretation of results</h4>
                            <p>In general, O-agglutinins appear towards the eighth day after the onset of fever, rise to a titre of about 400, and rapidly disappear after clinical cure. H-agglutinins appear about 10‚Äì12 days after the onset of fever, rapidly rise to a higher titre (800, to 1600), which decreases after the clinical cure. H-agglutinins can persist at a low titre (100 to 200) for several months, sometimes years after cure. Therefore, both O and H agglutinins of the infecting organism are present during the acute phase of the disease.</p>
                            <p>Generally, a titre of 80 or above is considered to be significant for H and O antibodies.</p>
                            <p>A second specimen of serum collected 10 to 14 days after the first should show a four fold rise in titre. This will indicate a true infection. If only O-agglutinins are observed in the first sample, this may correspond to the early stage of the typhoid or paratyphoid fever. The second sample will show both antibodies.</p>

                            <p><strong>Detection of Vi agglutinins</strong></p>
                            <p>Some fresh isolates of <em>Salmonella typhi</em> show an evidence of a surface antigen, Vi. Vi antigen is poorly immunogenic. The Vi antibodies appear after O and H agglutinins, and the titres are generally low. Vi antibodies, therefore, are not very useful in diagnosis. However, Vi antibodies can be detected only when the person harbours <em>S. typhi</em> in the body. Epidemiologically, it is useful for the detection of carriers.</p>
                            <p><strong>Interpretation:</strong> Vi agglutinins occur in sera of 80-90% of <em>S. typhi</em> carriers. The carrier state should be confirmed by isolation of the pathogen.</p>

                            <h3>B. Serodiagnosis of Brucellosis by Tube Agglutination Test</h3>
                            <p>Brucellosis in man is caused mainly by <em>Brucella abortus</em> and <em>Brucella melitensis</em>. Infection with <em>Brucella</em> species produces an antibody response and antibodies start appearing in the blood about 10 - 15 days after the onset of the disease. IgM antibodies are the first to appear followed by IgG. Generally, very high titres of antibodies are observed in brucellosis which can give false negative results due to prozone phenomenon. The slide agglutination test for screening is therefore, not recommended.</p>
                            <p><strong>Specimen:</strong> Serum, collected 10 to 15 days after the onset of the disease.</p>
                            <p><strong>Technique:</strong> Follow the same procedure as for the Widal test using the two Brucella antigens and 0.5% phenol saline as diluent. Incubate the tubes in 37¬∞C water bath for 24 to 48 hours.</p>
                            <p><strong>Interpretation:</strong> A titre of 80 and above indicates brucellosis. If the titre is less than 80, the test should be repeated with a second sample after 2‚Äì3 weeks. A two to four-fold rise in titre is indicative of current infection.</p>

                            <h3>C. Weil-Felix Test</h3>
                            <p>Weil-Felix test is an example of heterophile antibody test. This is based on the antibodies produced in acute rickettsial infections which crossreact with somatic antigens of OX19 and OX2 strains of <em>Proteus vulgaris</em> and OX K strain of <em>Proteus mirabilis</em>.</p>
                            <p><strong>Interpretation:</strong> A single titre of 160 or above; or a four-fold rise in paired sera at the interval of 2‚Äì3 weeks is suggestive of a rickettsial infection.</p>

                            <div class="table-wrapper">
                                <div class="table-header">
                                    <span class="table-icon">üìä</span>
                                    <span class="table-title">Table 5.1 Weil-Felix Reactions</span>
                                </div>
                                <div class="table-container">
                                    <table class="content-table">
                                        <thead>
                                            <tr>
                                                <th>Disease</th>
                                                <th>Agent</th>
                                                <th colspan="3" style="text-align: center;">Proteus Antigens</th>
                                            </tr>
                                            <tr>
                                                <th></th>
                                                <th></th>
                                                <th>OX19</th>
                                                <th>OX2</th>
                                                <th>OXK</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>Rocky Mountain spotted fever</td>
                                                <td>R. rickettsii</td>
                                                <td>++++</td>
                                                <td>+</td>
                                                <td>-</td>
                                            </tr>
                                            <tr>
                                                <td>Q fever</td>
                                                <td>C. burnetii</td>
                                                <td>-</td>
                                                <td>-</td>
                                                <td>-</td>
                                            </tr>
                                            <tr>
                                                <td>Endemic typhus</td>
                                                <td>R. typhi</td>
                                                <td>++++</td>
                                                <td>+</td>
                                                <td>-</td>
                                            </tr>
                                            <tr>
                                                <td>Brill-Zinsser</td>
                                                <td>R. prowazeki</td>
                                                <td>-/-</td>
                                                <td>-</td>
                                                <td>-</td>
                                            </tr>
                                            <tr>
                                                <td>Rickettsialpox</td>
                                                <td>R. akari</td>
                                                <td>-</td>
                                                <td>-</td>
                                                <td>-</td>
                                            </tr>
                                            <tr>
                                                <td>Epidemic typhus</td>
                                                <td>R. prowazeki</td>
                                                <td>++++</td>
                                                <td>+</td>
                                                <td>-</td>
                                            </tr>
                                            <tr>
                                                <td>Scrub typhus</td>
                                                <td>R. tsutsugamushi</td>
                                                <td>-</td>
                                                <td>-</td>
                                                <td>+++</td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 2: ASO Test -->
                    <section class="content-section" id="aso-test">
                        <div class="section-header">
                            <div class="section-number">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">üî¥</span>
                                Antistreptolysin-O (ASO) Test
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Streptolysin-O is an oxygen-labile haemolysin produced by many strains of group A,C and G streptococci. Streptolysin-O is immunogenic and induces antibody production in the host. Detection and titration of antistreptolysin-O antibodies is one of the most widely used methods of immunological diagnosis of post-streptococcal disorders such as rheumatic fever or glomerulonephritis. Conventional culture and identification methods are not possible in most cases because the organism is absent by the time the symptoms appear.</p>
                            
                            <p><strong>Principle:</strong> The antistreptolysin-O (ASO) test is an enzyme inhibition or neutralisation assay. Patient's serum is serially diluted and incubated with the streptolysin O. Antibody, if present in the patient's serum, will neutralise the streptolysin O. Inhibition of the haemolytic activity of streptolysin O can be detected by the addition of red cells to this mixture. Haemolysis of the red cells will indicate absence of ASO.</p>

                            <p><strong>Technique (Tube method)</strong></p>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) Dilute the serum samples 1:10, 1:100 and 1:500.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) Reconstitute ASO control serum with 10 ml of distilled water; this is equivalent to 1:100 dilution.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) Set up the test according to the protocol given in Table 5.2.</span></li>
                            </ul>

                            <div class="table-wrapper">
                                <div class="table-header">
                                    <span class="table-icon">üìä</span>
                                    <span class="table-title">Table 5.2 ASO test</span>
                                </div>
                                <div class="table-container">
                                    <table class="content-table content-table--compact">
                                        <thead>
                                            <tr>
                                                <th>Serum Dilutions</th>
                                                <th>1:10</th>
                                                <th></th>
                                                <th>1:100</th>
                                                <th></th>
                                                <th></th>
                                                <th></th>
                                                <th></th>
                                                <th>1:500</th>
                                                <th></th>
                                                <th></th>
                                                <th></th>
                                                <th></th>
                                                <th>Red Cell Control</th>
                                                <th>SLO Control</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>Tube</td>
                                                <td>1</td>
                                                <td>2</td>
                                                <td>3</td>
                                                <td>4</td>
                                                <td>5</td>
                                                <td>6</td>
                                                <td>7</td>
                                                <td>8</td>
                                                <td>9</td>
                                                <td>10</td>
                                                <td>11</td>
                                                <td>12</td>
                                                <td>13</td>
                                                <td>14</td>
                                            </tr>
                                            <tr>
                                                <td>Add serum dilution, ml</td>
                                                <td>0.8</td>
                                                <td>0.2</td>
                                                <td>1</td>
                                                <td>0.8</td>
                                                <td>0.6</td>
                                                <td>0.4</td>
                                                <td>0.3</td>
                                                <td>1</td>
                                                <td>0.8</td>
                                                <td>0.6</td>
                                                <td>0.4</td>
                                                <td>0.2</td>
                                                <td>0</td>
                                                <td>0</td>
                                            </tr>
                                            <tr>
                                                <td>Add buffer solution, ml</td>
                                                <td>0.2</td>
                                                <td>0.8</td>
                                                <td>0</td>
                                                <td>0.2</td>
                                                <td>0.4</td>
                                                <td>0.6</td>
                                                <td>0.7</td>
                                                <td>0</td>
                                                <td>0.2</td>
                                                <td>0.4</td>
                                                <td>0.6</td>
                                                <td>0.8</td>
                                                <td>1.5</td>
                                                <td>1</td>
                                            </tr>
                                            <tr>
                                                <td>Todd unit value</td>
                                                <td>12</td>
                                                <td>50</td>
                                                <td>100</td>
                                                <td>125</td>
                                                <td>166</td>
                                                <td>250</td>
                                                <td>333</td>
                                                <td>500</td>
                                                <td>625</td>
                                                <td>833</td>
                                                <td>1250</td>
                                                <td>2500</td>
                                                <td></td>
                                                <td></td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </div>
                            </div>

                            <p><strong>Interpretation:</strong> A titre of 200 Todd units or above is significant. Testing of paired sera at an interval of 10-15 days is recommended.</p>
                        </div>
                    </section>

                    <!-- Section 3: Syphilis -->
                    <section class="content-section" id="syphilis">
                        <div class="section-header">
                            <div class="section-number">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü¶†</span>
                                Serodiagnosis of Syphilis
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Serological tests for syphilis (STS) can be divided into two groups: tests using non-treponemal antigen and tests using treponemal (specific) antigens.</p>

                            <h3>Tests Using Non-treponemal Antigen</h3>
                            <p>In these tests antigens such as cardiolipin, is used to detect 'reagin' antibody. The reagin antibody is non-specific and is found in the sera of patients with T.pallidum infection. Venereal Disease Research Laboratory (VDRL) test and rapid plasma reagin (RPR) test are the two most commonly used non-specific tests.</p>

                            <h4>1. VDRL (Venereal Disease Research Laboratory) Test</h4>
                            <p><strong>Principle:</strong> This is a non-specific flocculation test. A cardiolipin-lecithin-cholesterol antigen is mixed with patient's serum, agitated and examined microscopically for flocculation.</p>
                            <p><strong>Result Interpretation:</strong></p>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reactive: medium to large sized clumps are seen</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Weakly Reactive: small clumps are seen</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Non-reactive: no clumps are seen</span></li>
                            </ul>

                            <h4>2. RPR (rapid plasma reagin) card test</h4>
                            <p>RPR is another non-treponemal flocculation test for the detection of reagin antibodies. The antigen is the VDRL antigen containing microparticulate carbon. This enhances the visual difference between a reactive and a non-reactive result.</p>

                            <h3>Tests Using Specific Treponemal Antigens</h3>
                            <p>These tests detect antibody to Treponema pallidum or its components, and therefore, are specific for the diagnosis of syphilis.</p>

                            <h4>1. Fluorescent treponemal antibody absorption test (FTA-ABS)</h4>
                            <p><strong>Principle:</strong> FTA-ABS is an indirect fluorescent antibody test, specific for the detection of antibody to <em>Treponema pallidum</em>. It is used as a confirmatory test in the diagnosis of syphilis. Serum samples are absorbed by treponemal protein extract of Reiter strain to eliminate non-specific antibodies from the sample. Serum dilutions are incubated with <em>Treponema pallidum</em> antigen fixed to slides.</p>

                            <div class="table-wrapper">
                                <div class="table-header">
                                    <span class="table-icon">üìä</span>
                                    <span class="table-title">Table 5.4 Grading of results of FTA-ABS</span>
                                </div>
                                <div class="table-container">
                                    <table class="content-table">
                                        <thead>
                                            <tr>
                                                <th>Reading</th>
                                                <th>Intensity of Fluorescence</th>
                                                <th>Report</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>2+ to 4+</td>
                                                <td>Moderate to strong</td>
                                                <td>Reactive (R)</td>
                                            </tr>
                                            <tr>
                                                <td>1+</td>
                                                <td>Equivalent to Minimally Reactive (1+) control</td>
                                                <td>Reactive (R)</td>
                                            </tr>
                                            <tr>
                                                <td>&lt;1+</td>
                                                <td>Weak but definite, less than Minimally reactive (1+) control</td>
                                                <td>Borderline (B)</td>
                                            </tr>
                                            <tr>
                                                <td>-</td>
                                                <td>None or vaguely visible</td>
                                                <td>Non-reactive (N)</td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </div>
                            </div>

                            <h4>2. Treponema Pallidum Haemagglutination (TPHA) Test</h4>
                            <p>TPHA is a simple specific test for syphilis. The test is comparable to FTA-ABS in all stages of syphilis except in the primary stage when the TPHA is less sensitive than the FTA-ABS or the VDRL test.</p>
                            <p><strong>Principle:</strong> Patient's serum is diluted and mixed with tanned turkey or chicken or sheep red cells coated with inactivated antigen from Nichol's strain of <em>T.pallidum</em>, in microtitre plate. The antibody in the patient's serum reacts with the antigen sensitised red cells to give an agglutination depicted by a characteristic pattern in the wells as the agglutinated cells settle to the bottom.</p>
                        </div>
                    </section>

                    <!-- Section 4: Hepatitis -->
                    <section class="content-section" id="hepatitis">
                        <div class="section-header">
                            <div class="section-number">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü©∫</span>
                                Serodiagnosis of Viral Hepatitis
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Hepatitis or inflammation of the liver is mainly caused by hepatitis viruses (HAV, HBV, HCV, HDV, HEV).</p>

                            <h3>1. Enzyme Immunoassay for Hepatitis‚ÄîA Virus</h3>
                            <p><strong>Principle:</strong> The IgM antibody to hepatitis A virus in patient's serum is captured by anti-IgM coated on a solid phase. Addition of hepatitis A virus (HAV) antigen followed by anti-HAV conjugated with an enzyme results in the formation of a complex. This complex can be detected by the addition of specific substrate and is indicated by a colour change.</p>
                            <p><strong>Interpretation:</strong> Presence of anti-HAV IgM in patient's serum indicates a current or recent infection with HAV. The test does not indicate the immune status to HAV because it does not measure anti-HAV IgG.</p>

                            <h3>2. Serodiagnosis of Hepatitis B</h3>
                            <p>HBsAg and HBeAg may be detected in the sera of infected individuals. These antigens and their homologous antibodies are considered to be the specific markers of hepatitis B infection.</p>
                            
                            <p><strong>Sequence of Hepatitis B markers</strong></p>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) <strong>HBsAg</strong> is the first to appear after exposure to HBV. The presence of HBsAg indicates active infection.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) <strong>HBeAg</strong> appears shortly after HBsAg. It indicates a high degree of infectivity and is present during viral replication.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) <strong>Anti-HBc</strong> can be detected shortly after the appearance of symptoms. IgM core antibody indicates a current or recent infection.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iv) <strong>Anti-HBe</strong> appears shortly after HBeAg disappears from the serum. The presence of this antibody indicates that the infection is being resolved.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(v) <strong>Anti-HBs</strong> appears after HBsAg disappears from blood and indicates a convalescent phase. It provides protective immunity.</span></li>
                            </ul>

                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251219-5615c6a7.jpeg" alt="Hepatitis markers in acute infection with hepatitis B virus" class="figure-image">
                                </div>
                                <figcaption class="figure-caption">Fig 5.1 Hepatitis markers in acute infection with hepatitis B virus</figcaption>
                            </figure>

                            <p><strong>Detection of HBsAg by ELISA:</strong> Beads or wells coated with mouse monoclonal antibody to HBsAg are incubated with patient's serum and with mouse anti-HBs conjugated with horseradish peroxidase. If HBsAg is present, it binds to both, forming a sandwich.</p>
                            
                            <p><strong>Calculation of Cut-off:</strong></p>
                            <div class="equation">
                                $$NCx + \frac{PCx}{10} = \text{cut-off value}$$
                            </div>
                            <p>Where NCx is mean of negative controls and PCx is mean of positive controls.</p>
                        </div>
                    </section>

                    <!-- Section 5: HIV/AIDS -->
                    <section class="content-section" id="hiv">
                        <div class="section-header">
                            <div class="section-number">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">üî¨</span>
                                Serodiagnosis of HIV Infection
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>ELISA or agglutination tests are used for screening patients and blood donors. More specific procedures such as Western blot should be used to confirm positive screening tests.</p>

                            <h3>ELISA for HIV Antibody</h3>
                            <p>ELISA is the most widely used method for the detection of HIV antibody. Commercial kits with very high (98% ‚Äì 99%) sensitivity and specificity are available.</p>
                            <p><strong>Principle:</strong> HIV virus coated beads or microtitre wells are incubated with patient's serum or plasma. If patient's serum contains HIV antibody, it binds to the antigen on the solid phase. After washing, antibody to human IgG conjugated with horseradish peroxidase is added. A yellow-orange colour after incubation with substrate indicates a positive test.</p>

                            <div class="callout callout--warning">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <h4 class="callout-title">Confirmation Required</h4>
                                </div>
                                <div class="callout-content">
                                    <p>If the serum is reactive after retesting, it must be reconfirmed by a confirmatory test such as the Western Blot (WB) technique which detects antibodies to individual HIV antigens.</p>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 6: Other Tests -->
                    <section class="content-section" id="other-tests">
                        <div class="section-header">
                            <div class="section-number">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">üìã</span>
                                Other Serodiagnostic Tests
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>TORCH Screening</h3>
                            <p>TORCH screening is a set of serological tests required as a part of investigations performed during early pregnancy. It includes tests for the detection of antibodies, particularly IgM antibodies, to:</p>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(i) Toxoplasma gondii (TO)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(ii) Rubella virus (R)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iii) Cytomegalovirus (C)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">(iv) Herpes simplex virus (H)</span></li>
                            </ul>

                            <h3>Serodiagnosis of Infectious Mononucleosis (IM)</h3>
                            <p>Diagnosis of IM depends on the haematological picture of severe lymphocytosis with more than 20% abnormal lymphocytes, and on the detection of heterophile antibodies.</p>
                            <p><strong>Monospot Test:</strong> This is a rapid slide test where patient's serum is treated with guinea pig kidney (does not absorb IM heterophile antibodies) and ox red cells (absorbs IM heterophile antibodies). Agglutination with horse red cells after guinea pig kidney treatment indicates a positive test.</p>

                            <h3>Rheumatoid Factor (RF) Screening Test</h3>
                            <p><strong>Principle:</strong> Latex particles coated with IgG, react with patient's serum containing RF. The RF acts as an antibody to IgG and attaches to the Fc portion of IgG on the latex particles, to bring about visible agglutination.</p>

                            <h3>Detection of Anti Nuclear Antibodies (ANA)</h3>
                            <p>Antinuclear antibodies (ANAs) are autoimmune antibodies which are directed against nuclei of tissue cells. They are found in the sera of patients suffering from SLE.</p>
                            <p><strong>Principle (IFA):</strong> Mouse liver or kidney cells are used as substrate nuclear antigens. The ANA in the patient's serum bind to the nuclear antigens. This antigen-antibody complex is detected by the addition of antiglobulin-fluorescein conjugate. This can be observed as a fluorescence under the fluorescent microscope.</p>
                        </div>
                    </section>

                    <!-- Key Points Section -->
                    <aside class="key-points-section" role="region" aria-labelledby="key-points-title">
                        <div class="key-points-wrapper">
                            <div class="key-points-header">
                                <span class="key-points-icon">‚≠ê</span>
                                <h3 id="key-points-title" class="key-points-title">Key Points</h3>
                            </div>
                            <ul class="key-points-list">
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Widal test is used for the diagnosis of enteric fevers (typhoid and paratyphoid).</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>A titre of 200 Todd units or above in ASO test is considered significant for post-streptococcal disorders.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>VDRL and RPR are non-specific screening tests for syphilis; TPHA and FTA-ABS are specific confirmatory tests.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>HBsAg is the first serological marker to appear in Hepatitis B infection.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>ELISA is the primary screening test for HIV; Western Blot is used for confirmation.</strong></p>
                                </li>
                            </ul>
                        </div>
                    </aside>

                </main>

                <!-- BOTTOM NAVIGATION -->
                <nav class="document-nav" role="navigation" aria-label="Document Navigation">
                    <div class="nav-links">
                        <a href="topic-04-in-vitro-reactions.html" class="nav-button nav-button--previous">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <a href="../index.html" class="nav-button">
                            <span class="nav-icon">üè†</span>
                            <span class="nav-text">Home</span>
                        </a>
                        
                        <a href="#" class="nav-button nav-button--next disabled" aria-disabled="true">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div>
                        </div>
                        <span class="progress-text">Topic 5 of 5</span>
                    </div>
                </nav>

            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div id="lightbox" class="lightbox-modal" hidden aria-hidden="true" role="dialog" aria-label="Image viewer">
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <!-- Scripts -->
    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>